<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375738</url>
  </required_header>
  <id_info>
    <org_study_id>4-2011-0109</org_study_id>
    <nct_id>NCT01375738</nct_id>
  </id_info>
  <brief_title>Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With Diabetes Mellitus</brief_title>
  <official_title>The Effect and Mechanism of Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With DM Who Receive Surgical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the effect of gastrectomy on remission of type 2 diabetes in
      patients with gastric cancer and type 2 diabetes, to investigate the mechanism of blood
      glucose alteration and intestinal hormonal signaling by the reconstruction methods, and to
      evaluate the applicability and efficacy of Roux-en-Y gastrojejunostomy after gastrectomy in
      gastric cancer patients with diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

        -  To investigate the effect of gastrectomy on remission of type 2 diabetes in patients
           with gastric cancer and type 2 diabetes

        -  To investigate the mechanism of blood glucose alteration and intestinal hormonal
           signaling by the reconstruction methods

        -  To evaluate the applicability and efficacy of Roux-en-Y gastrojejunostomy after
           gastrectomy in gastric cancer patients with diabetes

      Contents:

        -  Evaluation of the status of diabetes in gastric cancer patients with DM after
           gastrectomy

             -  Comparison of two reconstruction types after gastrectomy Bypass duodenum and upper
                jejunum: Roux-en-Y gastrojejunostomy Preservation of duodenal passage:
                Gastroduodenostomy

             -  Analysis for biochemical markers reflecting diabetic status: fasting glucose,
                postprandial 2h glucose, HbA1c, C-peptide, lipid profile

        -  Correlation of parameters associated with diabetes and GI hormones

             -  Measurement of GI hormones which have an effect on glucose tolerance

                  -  Insulin, glucagon, IGF-1, GLP-1, Neuropeptide Y, Ghrelin, Leptin

             -  Correlation of reconstruction methods, parameters of diabetes and GI hormone levels

             -  Evaluation of mechanism of Roux-en-Y gastrojejunostomy on controlling diabetes

        -  Evaluation of Feasibility of Roux-en-Y gastrojejunostomy in gastric cancer surgery in
           patients with DM

             -  Degree of high blood glucose control, the amount of antidiabetic medication, costs
                for DM treatment, quality of life assessment

             -  Analysis for the mechanism of gastrointestinal physiology to diabetes control
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood sugar stabilization after gastrectomy</measure>
    <time_frame>three months after surgery</time_frame>
    <description>By comparing the difference between fasting blood sugar and postprandial blood glucose, blood sugar stabilization after gastrectomy will be maesured.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Gastroduodenostomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux-en Y gastrojejunostomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en Y gastrojejunostomy</intervention_name>
    <description>After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30~40cm from the new gastric-jejunal junction.</description>
    <arm_group_label>Roux-en Y gastrojejunostomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastroduodenostomy</intervention_name>
    <description>After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.</description>
    <arm_group_label>Gastroduodenostomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who are older than 20 years and younger than 80 years

          -  Histologically confirmed gastric adenocarcinoma located lower one third of stomach

          -  Postoperative confirmed pT1N0, pT2N0, pT1N1

          -  Informed consent

        Exclusion Criteria:

          -  Previous history of treatment for other malignancy or inflammatory disease

          -  Preoperative uncontrolled serious comorbidity

          -  Vulnerable Subjects(pregnant women, children, cognitively impaired persons etc.)

          -  Patient who experience any complications requiring reoperation following gastrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Yeong An, MD</last_name>
      <phone>82-2-2228-2100</phone>
      <email>jar319@yuhs.ac</email>
    </contact>
    <contact_backup>
      <last_name>Yoo-Min Kim, MD</last_name>
      <email>AUG79@yuhs.ac</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Yang J, Li C, Liu H, Gu H, Chen P, Liu B. Effects of subtotal gastrectomy and Roux-en-Y gastrojejunostomy on the clinical outcome of type 2 diabetes mellitus. J Surg Res. 2010 Nov;164(1):e67-71. doi: 10.1016/j.jss.2010.07.004. Epub 2010 Jul 30.</citation>
    <PMID>20863527</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>ji yeong an</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <keyword>Early gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

